China Pharmaceutical University has prepared and tested sphingomyelin phosphodiesterase (SMPD1; aSMase) inhibitors potentially useful for the treatment of cancer, autoimmune disease, chronic obstructive pulmonary disease (COPD), Alzheimer’s disease, depression, diabetes, hepatic steatosis and stroke, among others.